About Us

We’re delivering ssDNA for tomorrow’s
gene therapies and technologies

At Moligo we have developed a novel enzymatic synthesis technology that generates DNA strands with unprecedented purity, length and complexity, and at industrial scale. We support partners developing new gene-based therapies and technologies with the mission of making them better, safer and accessible for everyone.

Our Story

Making Superior DNA for Tomorrow’s Genetic Medicines Safe, Effective, and Affordable for All 

Moligo Technologies was founded in 2019 by Karolinska Institutet scientists who recognized the crucial role of ultrapure long DNA oligonucleotides in revolutionizing gene-based technologies and therapies and making them accessible to all.

Our founders knew that traditional chemical DNA synthesis approaches were limiting the potential of new genetic medicines because of shortcomings in length and purity, and that fermentation-based productions carry bacterial or viral sequences and are limited in complexity and scalability. We also saw that emerging enzymatic DNA writing technologies lacked the ability to scale sufficiently to support the mass production of new medicines.

Moligo developed a novel patented Enzymatic Injection Molding Technology to close this gap by producing long, ultrapure, single-stranded DNA at industrial scale.  

The core mission of Moligo is clear: to advance gene technologies and therapies, enhancing their safety, efficacy, and affordability for all.

Our Mission

Partnering to Advance Genetic Medicine and Beyond 

Today, Moligo is utilizing its proprietary enzymatic DNA synthesis technology to generate customized ultrapure single-stranded DNA for leading companies and academic institutions in genetic medicine worldwide. We are also establishing co-development programs with biotech and pharma to exploit the power of our DNA synthesis technology to deliver a new class of gene-based technologies and therapies. 

Moligo Technologies is a privately-owned biotechnology company, backed by an impressive network of family offices and specialist healthcare investors.

Our Vision

The Future of DNA-based Technologies and Therapies

We envision a future where ultrapure, long DNA molecules, readily available at scale, will unlock myriad new possibilities across industries, from revolutionary diagnostics to innovative agricultural applications such as precision crop editing and DNA-based anti-insecticides.

We believe long, ultrapure DNA will pave the way for the development of novel biomaterials crucial for advancements in nanotechnology and bioelectronics, and will enhance research tools for spatial transcriptomics, providing deeper insights into the spatial organization of gene expression within tissues.

Moligo was founded on the belief that exceptional products are inevitable when we bring innovative minds together within state-of-the-art facilities to cultivate a vibrant, cutting-edge environment.  We are dedicated to seeking out, hiring, and retaining exceptionally talented individuals. This ethos has generated a remarkable culture that champions creativity, and fosters a rich diversity throughout our team by enticing, nurturing, and rewarding employees.

Our Values

  • Encouraging creativity and new ideas to drive progress.

  • Gaining the trust of our customers, employees, and extended family through transparency, security, compliance, privacy, and a commitment to excellence.

  • Prioritizing excellence in every aspect of our operations, ensuring that our products and services meet the highest standards of safety, reliability, and effectiveness.

Moligo is supported by

  • Nordic Innovation House